Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate.
Johanna Karlsson SundbaumEva BaecklundNiclas ErikssonHugo KohnkeMatilda WallenbergMarco CavalliClaes WadeliusMia WadeliusPär HallbergPublished in: Pharmacogenomics (2021)
Aim: To identify novel genetic variants predisposing to elevation of Alanine aminotransferase (ALT) in rheumatoid arthritis (RA) patients after initiation of methotrexate (MTX) treatment. Patients & methods: We performed genome-wide association studies in 198 RA patients starting MTX. Outcomes were maximum level of ALT and ALT >1.5-times the upper level of normal within the first 6 months of treatment. Results: RAVER2 (rs72675408) was significantly associated with maximum level of ALT (p = 4.36 × 10-8). This variant is in linkage disequilibrium with rs72675451, which is associated with differential expression of JAK1 and RAVER2. Conclusion: We found an association between ALT elevation and genetic variants that may regulate the expression of JAK1 and RAVER2. JAK1 encodes a janus kinase involved in the pathogenesis of RA.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- disease activity
- rheumatoid arthritis patients
- prognostic factors
- type diabetes
- ankylosing spondylitis
- high dose
- poor prognosis
- metabolic syndrome
- gene expression
- tyrosine kinase
- patient reported outcomes
- hepatitis c virus
- long non coding rna
- adipose tissue
- weight loss
- protein kinase
- case control